We conducted a phase II trial (NCT02879994) of pembrolizumab in TKI naive patients with EGFR mutation–positive, advanced NSCLC and PD-L1–positive (≥1%, 22C3 antibody) tumors. Pembrolizumab was administered 20
Study design and intervention:This study is a phase II, open label study (NCT06536374) randomizing patients starting ADT for prostate cancer to trimethoprim 150 mg OD for 3 months+standard of care (SOC) versus SOC alone. Randomization will occur between groups in a 1:1 ratio using computer ...
Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients (NSCLCm+). This phase II trial (NCT04201756) aimed to assess the feasibility of neoad
Bui B, Theodore C, Culine S De Santis M, Demkow T, Lorenz J, Rolland F, Fabry F, Pouget JC, James N (2003) Preliminary results of a phase II study testing intravenous (IV) vinflunine as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Pro...
Participants had stable disease at screening and baseline, with lesions in 2 or more distinct anatomical areas (≥1 at Hurley stage II/III), a total abscess and inflammatory nodule (AN) count of 3 or more, and a C-reactive protein level greater than 0.30 mg/dL (to convert to milligrams...
et al. Feasibility of protein-sparing modified fast by tube (ProMoFasT) in obesity treatment: a phase II pilot trial on clinical safety and efficacy (appetite control, body composition, muscular strength, metabolic pattern, pulmonary function test). Mediterr J Nutr Metab 6, 165–176 (2013). ...
Patients with primary liver cancer were prospectively enrolled into a phase II-study on the evaluation of technical complications associated with the use of interventionally implanted port catheter systems (IIPCS) in patients with cancers confined to the liver between 2004 and 2010 (ClinicalTrials.gov...
Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance responses to PD-1 inhibitors through the induction of tumor-specific immunity. We present results from a single-ar...
In an open label, single arm, non-randomized, unblinded phase II study in patients with locally advanced or meta-static breast cancer who had been previously treated with one anthracycline with/without taxane-based regimen in the adjuvant/neoadjuvant or first-line metastatic setting, we studied th...
A phase II trial, including 67 hormone-naive prostate cancer (15% with metastatic disease) patients for whom hormone therapy was indicated and who had non-castration levels of testosterone, evaluated the efficacy of enzalutamide 160 mg/day and showed PSA decline of 80% or greater at week 25 ...